Since p16 was first discovered in 1993, great progress has been made in establishing p16 as a tumor suppressor and delineating the p16/CDK/cyclin D pathway as a key regulator of cell proliferation [81,82]. The gene discussed is CDKN2A; the disease is neoplasm.